Cargando...

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

BACKGROUND: Nucleoside reverse transcriptase inhibitors (NRTIs) may contribute to or exacerbate cardiovascular risk, bone loss, and renal dysfunction. Darunavir (DRV) and dolutegravir (DTG) have a high barrier to resistance and proven tolerability profile, but have not been well studied as part of a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Autores principales: Verna, John, Austin, Stephen
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255063/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.561
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!